Pelabresib May Represent Optimal Partner for JAK Inhibition in Myelofibrosis

[Manouche]

The benefits yielded with the BET inhibitor pelabresib (formerly CPI-0610) in patients with myelofibrosis are multifold, and the agent’s potential to improve disease biology and overcome shortcomings faced with JAK inhibitors make it a strong partner for combinations and a stand-out option vs other agents under exploration in the paradigm, according to Prithviraj Bose, MD »

« What I did not mention earlier is that pelabresib lead to bone marrow fibrosis improvement of 1 grade or higher in 20% to 40% of patients if we [consider] all the arms of the MANIFEST trial. What is quite striking is that this [improvement] happened within 6 months; it happened very quickly. We consider bone marrow fibrosis improvement to be something that takes a lot of time, so one could imagine that with longer exposure, we are going to see even better bone marrow fibrosis improvement, hopefully of 2 grades or more. »

onclive.com/view/pelabresib...

[DJW1]

I have been fortunate to recently (as in last week) start on the trial for CPI 0160. I will keep you updated on how effective it is in my case.